Characteristic | Conventional group (n = 101) | Combined group (n = 102) | P | |
---|---|---|---|---|
Sex | Â | Â | 0.254 | |
 | Male | 80 (79.2%) | 73 (71.6%) |  |
 | Female | 21 (20.8%) | 29 (28.4%) |  |
Age | Median (IQR, years) | 57 (50–65) | 61 (51-67.25) | 0.151 |
 | < 60 years | 59 (58.4%) | 49 (48%) | 0.16 |
BMI | Median (IQR, kg/m2) | 21.64 (20.24–24.22) | 22.15 (20.48–24.22) | 0.637 |
Smoking | 59 (58.4%) | 60 (58.8%) | 1 | |
Drinking | 53 (52.5%) | 59 (57.8%) | 0.482 | |
Comorbidity | Â | Â | Â | Â |
 | Hypertension | 14 (13.9%) | 16 (15.7%) | 0.844 |
 | Coronary heart disease | 3 (3%) | 4 (3.9%) | 1 |
 | Diabetes | 14 (13.9%) | 8 (7.8%) | 0.183 |
 | Other | 15 (14.9%) | 12 (11.8%) | 0.542 |
Family history | 4 (4%) | 7 (6.9%) | 0.537f | |
ASA | Â | Â | Â | 0.622 |
 | 1 | 2 (2%) | 1 (1%) |  |
 | 2 | 63 (62.4%) | 56 (54.9%) |  |
 | 3 | 35 (34.6%) | 44 (43.1%) |  |
 | 4 | 1 (1%) | 1(1%) |  |
Pretreatment Hb (IQR, g/L) | 118 (86–133) | 125 (92–139) | 0.17 | |
Pretreatment neutrophils (IQR, *108) | 3.74 (3.09–4.76) | 3.72 (2.92–4.92) | 0.969 | |
Pretreatment lymphocyte (IQR, *108) | 1.37 (1.06–1.68) | 1.41 (1.13–1.73) | 0.574 | |
Pretreatment platelet (IQR, *108) | 243 (203–351) | 235 (181–307) | 0.235 | |
Pretreatment albumin (IQR, g/L) | 38 (34–41) | 31 (33–40) | 0.567 | |
Pretreatment CEA(>5.2 ng/ml) | 36 (35.6%) | 26 (25.5%) | 0.129 | |
Pretreatment CA19-9 (> 27 U/ml) | 34 (33.7%) | 29 (28.4%) | 0.451 | |
Tumor location | Â | Â | 0.766 | |
 | Upper stomach | 35 (34.6%) | 36 (35.3%) |  |
 | Middle stomach | 22 (21.8%) | 26 (25.5%) |  |
 | Lower stomach | 44 (43.6%) | 40 (39.2%) |  |
Tumor size (IQR, cm) | 6 (5-7.7) | 5.57 (4.6–6.8) | 0.236 | |
Borrmann typing | Â | Â | 0.49 | |
 | I | 26 (25.7%) | 34 (33.3%) |  |
 | II | 12 (11.9%) | 12 (11.8%) |  |
 | III | 51 (34.6%) | 49 (48%) |  |
 | IV | 12 (11.9%) | 7 (6.9%) |  |
Clinical T stage | Â | Â | 0.859 | |
 | T3 | 24 (23.8%) | 27 (26.5%) |  |
 | T4a | 70 (69.3%) | 67 (65.7%) |  |
 | T4b | 7 (6.9%) | 8 (7.8%) |  |
Clinical N stage | Â | Â | 0.374 | |
 | N0 | 11 (10.9%) | 17 (16.7%) |  |
 | N1 | 29 (28.7%) | 27 (26.5%) |  |
 | N2 | 42 (41.6%) | 46 (45.1%) |  |
 | N3 | 19 (18.8%) | 12 (11.8%) |  |
Clinical TNM stage | Â | Â | 0.825 | |
 | IIa | 2 (2%) | 3 (2.9%) |  |
 | IIb | 16 (15.8%) | 22 (21.6%) |  |
 | IIIa | 31 (30.7%) | 30 (29.4%) |  |
 | IIIb | 35 (34.7%) | 33 (32.4%) |  |
 | IIIc | 17 (16.8%) | 14 (13.7%) |  |
Chemotherapy regimen | Â | Â | 0.152 | |
 | NPOS | 56 (55.4%) | 67 (65.7%) |  |
 | DOS | 45 (44.6%) | 35 (34.3%) |  |
Number of neoadjuvant therapy cycles | Â | Â | 0.175 | |
 | 2 | 49 (48.5%) | 57 (55.9%) |  |
 | 3 | 40 (39.6%) | 40 (39.2%) |  |
 | 4 | 12 (11.9%) | 5(4.9%) |  |
Number of chemoembolization | Â | Â | Â | |
 | 1 |  | 91 (89.2%) |  |
 | 2 |  | 11(10.8%) |  |